Surgery remains the gold standard for small renal masses [16]. Current National Comprehensive Cancer Network guidelines recommend partial nephrectomy as the preferred treatment for stage 1A kidney cancer. The guidelines include ablation as a primary treatment option in select patients. Ablation can be performed either laparoscopically or percu­taneously. While laparoscopic cryoablation has shown to have fewer complications and result in shorter hospital stays compared with laparoscopic or robotic partial nephrectomy, the ablation group also had higher rates of local tumor pro­gression and metastases [17]. A large retrospective study from Thompson etal. demonstrated similar recurrence-free survival between partial nephrectomy, percutaneous cryoab­lation, and percutaneous radiofrequency ablation [18]. However, metastases-free survival was higher for both par­tial nephrectomy and cryoablation compared to radiofre­quency ablation. The partial nephrectomy group had superior overall survival; however, the population was younger and healthier compared to the ablation groups. A 2008 meta­analysis comparing percutaneous to laparoscopic tumor ablation using both cryoablation and radiofrequency ablation demonstrated higher primary effectiveness within the surgi­cal group, 94% versus 87%, respectively [19]. However, with secondary effectiveness, the percutaneous ablation group achieved 95% effectiveness. Additionally, major com­plications were 7% for laparoscopic ablation compared to 3% for percutaneous ablation.